News

Empty gabapentin capsules spur recall


 

References

Following the discovery of capsules found to be empty, Aurobindo Pharma USA has initiated a recall of the epilepsy treatment gabapentin, the company announced Nov. 21.

The company is voluntarily recalling lot GESB14011-A of 100-count bottles of 300 mg gabapentin, which have an expiration date of December 2015. The product also is used to manage postherpetic neuralgia.

The Food and Drug Administration noted that the empty capsules could result in missed doses, potentially resulting in no effect, short-term efficacy reduction, short-term withdrawal effect, or status epilepticus that could be life threatening.

gtwachtman@frontlinemedcom.com

Recommended Reading

Buprenorphine tapering far less effective than maintenance
MDedge Family Medicine
ACR 2010 criteria for fibromyalgia critiqued
MDedge Family Medicine
Prescription opioids linked to majority of opioid overdoses
MDedge Family Medicine
Brain changes identified in chronic fatigue syndrome
MDedge Family Medicine
Abrupt abdominal pain
MDedge Family Medicine
High-dose opioids mainly prescribed in offices, not the ED
MDedge Family Medicine
Comborbidities likely explain opioid + sleep apnea mortality risk
MDedge Family Medicine
Current use of COX-2 inhibitors linked to increased mortality after ischemic stroke
MDedge Family Medicine
NSAIDs linked to serious bleeding, thromboembolism in AF patients
MDedge Family Medicine
FDA approves extended-release hydrocodone with abuse-deterrent features
MDedge Family Medicine